6533b7d9fe1ef96bd126c383
RESEARCH PRODUCT
Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial.
Fp StrietzelGi LafaurieGr Bautista MendozaI AlajbegS PejdaL VuleticR MantillaDp FalcaoSc LealAc Barreto BezerraSd TranHa MenardS KimotoS PanMartin GranizoManiegas LozanoRa LSl ZuntCa KrushinskiDario MelilliGiuseppina CampisiCarlo PaderniS DolceJf YepesL LindhM KorayG MumcuS EladI ZeeviBc Aldape BarriosRm Lopez SanchezBz BeiskiA WolffYt Konttinensubject
AdultMalemedicine.medical_specialtyImmunologySettore MED/50 - Scienze Tecniche Mediche ApplicateElectric Stimulation TherapySeverity of Illness IndexXerostomialaw.inventionRandomized controlled trialQuality of lifestomatognathic systemRheumatologyDouble-Blind MethodlawSettore MED/28 - Malattie OdontostomatologicheMulticenter trialSeverity of illnessotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansPharmacology (medical)Prospective StudiesOral mucosaProspective cohort studyAgedxerostomia; dry mouth; salivary gland hypofunction; saliva; electrical stimulation; electrostimulation; Sjögren’s syndromeIntention-to-treat analysisToxicitybusiness.industryMouth MucosaMiddle AgedDry mouthSurgeryOral cavityIntention to Treat Analysisstomatognathic diseasesmedicine.anatomical_structureSjogren's SyndromeTreatment OutcomeAnesthesiaFemalemedicine.symptombusinessdescription
Objective To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia. The device delivers electrostimulation through the oral mucosa to the lingual nerve in order to enhance the salivary reflex. Methods The device was tested on a sample of patients with xerostomia due to Sjogren's syndrome and other sicca conditions in a 2-stage prospective, randomized, multicenter trial. Stage I was a double-blind, crossover stage designed to compare the effects of the electrically active device with the sham device, each used for 1 month, and stage II was a 3-month open-label stage designed to assess the long-term effects of the active device. Improvement in xerostomia severity from baseline was the primary outcome measure. Results A total of 114 patients were randomized. In stage I, the active device performed better than the sham device for patient-reported xerostomia severity (P < 0.002), xerostomia frequency (P < 0.05), quality of life impairment (P < 0.01), and swallowing difficulty (P < 0.02). At the end of stage II, statistically significant improvements were verified for patient-reported xerostomia severity (P < 0.0001), xerostomia frequency (P < 0.0001), oral discomfort (P < 0.001), speech difficulty (P < 0.02), sleeping difficulty (P < 0.001), and resting salivary flow rate (P < 0.01). Conclusion Our findings indicate that daily use of the device alleviated oral dryness, discomfort, and some complications of xerostomia, such as speech and sleeping difficulties, and increased salivary output. The results show a cumulative positive effect of the device over the period of the study, from baseline to the end of the trial.
year | journal | country | edition | language |
---|---|---|---|---|
2011-01-01 | Arthritis and rheumatism |